Anika Q2 revenue rises 12% to $44.3M; raises FY2023 guidance floor to $159.5M

Anika Therapeutics, Inc.

2023-Q2 EPS reported -$0.89 revenue$82,226,000

Q2 revenue $44.3M (+12% YoY); net loss ($0.19)/share; adjusted EPS $0.06 vs ($0.12) prior year.
OA Pain Mgmt rev +22% to $29.3M; Joint Preservation & Restoration +5% to $12.7M.
FY2023 rev guidance raised: $159.5M-$163M (was $158M-$163M), representing 2-4% growth.
Hyalofast Phase III fully enrolled; PMA submission begins 2024; Cingal ongoing FDA discussions after Type-C meeting.
RevoMotion reverse shoulder full market launch accelerated to Sept 2023; Integrity rotator cuff patch 2024 launch on track.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Anika Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $44.3 million, net income ($2.7) million, or ($0.19) per share, EPS ($0.19) per share. Guidance raised.

Period: the second quarter ended June 30, 2023
Revenue: $44.3 million
Net income: ($2.7) million, or ($0.19) per share
EPS: ($0.19) per share
Guidance: raised
Result: reported results

Exact text from the filing

Revenue in the second quarter of 2023 was $44.3 million, up 12% compared to $39.7 million in the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-005107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.